Emergent Biosolutions (EBS) to Release Earnings on Wednesday

Emergent Biosolutions (NYSE:EBS) will likely be announcing its Q3 2025 results after the market closes on Wednesday, October 29th. Analysts expect the company to announce earnings of ($0.01) per share and revenue of $203.6670 million for the quarter. Emergent Biosolutions has set its FY 2023 guidance at EPS.Investors may visit the the company’s upcoming Q3 2025 earningresults page for the latest details on the call scheduled for Wednesday, October 29, 2025 at 5:00 PM ET.

Emergent Biosolutions (NYSE:EBS) last issued its earnings results on Tuesday, January 9th. The biopharmaceutical company reported ($1.27) earnings per share (EPS) for the quarter. The business had revenue of $222.50 million during the quarter. Emergent Biosolutions had a net margin of 16.38% and a return on equity of 24.63%. On average, analysts expect Emergent Biosolutions to post $-1 EPS for the current fiscal year and $2 EPS for the next fiscal year.

Emergent Biosolutions Stock Down 3.8%

Shares of NYSE EBS opened at $9.46 on Wednesday. The firm has a market capitalization of $504.69 million, a PE ratio of 3.86 and a beta of 2.04. The company has a current ratio of 5.66, a quick ratio of 3.00 and a debt-to-equity ratio of 1.25. Emergent Biosolutions has a 1 year low of $4.02 and a 1 year high of $12.73. The firm’s 50-day moving average is $8.73 and its 200-day moving average is $7.06.

Wall Street Analyst Weigh In

Several research analysts have recently issued reports on EBS shares. HC Wainwright reaffirmed a “buy” rating and issued a $15.00 target price on shares of Emergent Biosolutions in a research note on Wednesday, September 3rd. Weiss Ratings reaffirmed a “sell (d)” rating on shares of Emergent Biosolutions in a research note on Wednesday, October 8th. Finally, Wall Street Zen lowered shares of Emergent Biosolutions from a “buy” rating to a “hold” rating in a research note on Saturday, August 9th. Two equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus target price of $13.50.

Insider Activity at Emergent Biosolutions

In related news, Director Kathryn C. Zoon sold 7,086 shares of the business’s stock in a transaction that occurred on Friday, August 15th. The shares were sold at an average price of $8.87, for a total transaction of $62,852.82. Following the completion of the transaction, the director owned 71,799 shares in the company, valued at approximately $636,857.13. The trade was a 8.98% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Donald W. Degolyer sold 7,844 shares of the business’s stock in a transaction that occurred on Tuesday, August 12th. The shares were sold at an average price of $8.65, for a total transaction of $67,850.60. Following the transaction, the director owned 137,659 shares of the company’s stock, valued at approximately $1,190,750.35. This represents a 5.39% decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 45,538 shares of company stock worth $436,783. 3.20% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the stock. Legal & General Group Plc acquired a new position in shares of Emergent Biosolutions in the second quarter valued at approximately $31,000. Brevan Howard Capital Management LP boosted its holdings in shares of Emergent Biosolutions by 44.2% in the second quarter. Brevan Howard Capital Management LP now owns 18,724 shares of the biopharmaceutical company’s stock valued at $119,000 after buying an additional 5,743 shares during the period. Raymond James Financial Inc. acquired a new position in shares of Emergent Biosolutions in the second quarter valued at approximately $53,000. State of Wyoming boosted its holdings in shares of Emergent Biosolutions by 32.5% in the second quarter. State of Wyoming now owns 41,315 shares of the biopharmaceutical company’s stock valued at $264,000 after buying an additional 10,127 shares during the period. Finally, Headlands Technologies LLC acquired a new position in shares of Emergent Biosolutions in the second quarter valued at approximately $115,000. Institutional investors and hedge funds own 78.40% of the company’s stock.

About Emergent Biosolutions

Emergent BioSolutions Inc, a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax.